Mylan Offering Possible 12.11% Return Over the Next 9 Calendar Days

Mylan's most recent trend suggests a bullish bias. One trading opportunity on Mylan is a Bull Put Spread using a strike $46.00 short put and a strike $41.00 long put offers a potential 12.11% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $46.00 by expiration. The full premium credit of $0.54 would be kept by the premium seller. The risk of $4.46 would be incurred if the stock dropped below the $41.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Mylan is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Mylan is bullish.

The RSI indicator is at 62.34 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


Mylan Schedules Fourth Quarter and Year End 2013 Financial Results Conference Call and Live Webcast
Tue, 11 Feb 2014 15:20:00 GMT
PR Newswire – PITTSBURGH, Feb. 11, 2014 /PRNewswire/ — Mylan Inc. (MYL) announced today that it will host a conference call and live webcast, including a slide presentation, on Thursday, Feb. 27, 2014, at 10:00 a.m. ET, to review the company's financial results for the fourth quarter and year ended Dec. 31, 2013. The company also will be providing its financial guidance for 2014. Mylan will release its financial results on Feb. 27 before the market opens. The dial-in number to access the call is 800.514.4861 or 678.809.2405 for international callers. A replay, available for approximately seven days, will be available at 855.859.2056 or 404.537.3406 for international callers;

Generic-Drug Makers Actavis, Mylan To Report Q4 Soon
Mon, 10 Feb 2014 22:40:00 GMT

Roche bans rivals from comparing copycat drugs to Herceptin
Fri, 07 Feb 2014 16:33:44 GMT
Reuters – Pharmaceutical group Roche said it secured an injunction from an Indian court banning generic drug makers Biocon and Mylan from comparing their copycat versions of Roche's Herceptin breast cancer treatment to the original. Mylan and Biocon, which co-developed breast cancer drugs CANMab and Hertraz they say are biosimilars of Herceptin, are no longer allowed to refer to Herceptin or its manufacturing process, safety, efficacy and sales when communicating about their drugs, the New Delhi High Court ruled on Wednesday.

Pfizer beats back generic competition for Lyrica
Thu, 06 Feb 2014 18:01:17 GMT
Reuters – Pfizer Inc, the world's largest drugmaker, has beaten back generic competition for the pain medicine Lyrica, its biggest product, with a U.S. appeals court ruling that competing generic products would infringe on the company's patents. The U.S. Court of Appeals for the Federal Circuit, which handles all patent appeals, ruled on Thursday that Teva Pharmaceuticals USA Inc, Lupin Ltd, Actavis Inc and other generic competitors had infringed on Pfizer's patents. The decision upholds a ruling by the U.S. District Court for the District of Delaware that said that the generic versions may not be sold.

Mylan Rolls out Herceptin Biosimilar in India
Mon, 03 Feb 2014 16:10:04 GMT

Be Sociable, Share!

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.